Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230241 | 1.00 | PARL (0.34) | PARLALDH1A1PKMKMT2AATM | |
| SCHEMBL9513159 | 0.80 | — | — | |
| SCHEMBL1140513 | 0.78 | ALDH1A1 (0.33) | PARLALDH1A1PKMKMT2AATM | |
| SCHEMBL9150133 | 0.78 | ALDH1A1 (0.33) | PARLALDH1A1PKMKMT2AATM | |
| SCHEMBL28511792 | 0.74 | SMN1; SMN2 (0.37) | PARLALDH1A1PKMKMT2AATM | |
| SCHEMBL11989420 | 0.70 | PARL (0.31) | PARLKMT2AATM | |
| SCHEMBL13900968 | 0.70 | PARL (0.31) | PARLKMT2AATM | |
| SCHEMBL18914913 | 0.70 | GLA (0.33) | ALDH1A1KMT2AATM | |
| SCHEMBL57128 | 0.69 | PARL (0.38) | PARLKMT2AATMCA12CA1 | |
| SCHEMBL9976427 | 0.69 | PARL (0.33) | PARL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | claimed |
| US-20140037699-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569231-B2 | Soluble non-depot insulin conjugates and uses thereof | SMARTCELLS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037699-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | PARL 4650/4885ALDH1A1 3703/4885PKM 2203/4885 |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | PARL 4650/4885ALDH1A1 3703/4885PKM 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.